Key result
Ribonucleases possess established antiviral effects and are perspective agents for the development of new antiviral therapeutics.
Ribonucleases act as components of immune defense and hold potential for the development of novel antiviral therapeutics.
Ribonucleases merit exploration as antivirals; leaves open prospective human trials before clinical consideration.
Many ribonucleases (RNases) are able to inhibit the reproduction of viruses in infected cell cultures and laboratory animals, but molecular mechanisms of their antiviral activity remain unclear. The review observes the most known RNases which possess established antiviral effects, actually intracellular RNases (RNase L, MCPIPI protein, eosinophylic RNases) as well as exogenously applied ones (RNase A, BS-RNase, onconase, binase, synthetic RNases). Attention is given on two important but not always obligatory aspects in molecule of RNases, which have antiviral properties: catalytic activity and ability to the dimerization. The hypothetic scheme of virus elimination by exogenous RNases, that reflects possible types of interaction of viruses and RNases with a cell, is proposed. The evidence for RNases as classical components of immune defense which are perspective agents for development of new antiviral therapeutics is produced.
No takes yet. Share an insight, caveat, or question.
Ilinskaya et al. (2014) conducted a review in Viral infections. Ribonucleases (RNases) was evaluated. Ribonucleases possess established antiviral effects and are perspective agents for the development of new antiviral therapeutics.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: